Highly active antiretroviral therapy and viral response in HIV type 2 infection. - Wikidata - wikimedia - TriplyDB

Highly active antiretroviral therapy and viral response in HIV type 2 infection.

Highly active antiretroviral therapy and viral response in HIV type 2 infection.

http://www.wikidata.org/entity/Q34548972

about

Antiretroviral therapy response among HIV-2 infected patients: a systematic review Transmitted drug resistance, selection of resistance mutations and moderate antiretroviral efficacy in HIV-2: analysis of the HIV-2 Belgium and Luxembourg database Cell-associated viral burden provides evidence of ongoing viral replication in aviremic HIV-2-infected patients Human immunodeficiency virus type 2 in two Saudi families.Diagnoses of HIV-1 and HIV-2 in England, Wales, and Northern Ireland associated with west Africa.In vitro selection and characterization of human immunodeficiency virus type 2 with decreased susceptibility to lopinavir Immunologic response in treatment-naïve HIV-2-infected patients: the IeDEA West Africa cohort.Emergence of multiclass drug-resistance in HIV-2 in antiretroviral-treated individuals in Senegal: implications for HIV-2 treatment in resouce-limited West Africa A call for randomized controlled trials of antiretroviral therapy for HIV-2 infection in West Africa.Tenets of protection from progression to AIDS: lessons from the immune responses to HIV-2 infection.Virological response to highly active antiretroviral therapy in patients infected with human immunodeficiency virus type 2 (HIV-2) and in patients dually infected with HIV-1 and HIV-2 in the Gambia and emergence of drug-resistant variants.Comparison of viro-immunological marker changes between HIV-1 and HIV-2-infected patients in France.Cohort Profile: The Bissau HIV Cohort-a cohort of HIV-1, HIV-2 and co-infected patients.Quantitative detection of plasma human immunodeficiency virus type 2 subtype A RNA by the Nuclisens EasyQ Assay (version 1.1).Immunovirological response to triple nucleotide reverse-transcriptase inhibitors and ritonavir-boosted protease inhibitors in treatment-naive HIV-2-infected patients: The ACHIEV2E Collaboration Study Group.Susceptibility to protease inhibitors in HIV-2 primary isolates from patients failing antiretroviral therapy.

P2860

Q27003854-C7715E4E-18B0-40A5-9AFD-A08B18775FE0 Q33321434-7850D2B9-B602-4D56-93DD-25C83767234F Q34742090-1A187265-B739-4213-A837-11949A6081B6 Q35165841-E6DFBD81-E52D-4D69-8C07-87021E18238E Q35531822-1258E266-1FC4-462A-8272-A1827591F23C Q36094944-15039990-0ED7-405A-9CBA-2CB25326D721 Q36564668-D9D16CAD-9E76-4B2F-8F19-1F7E2B7CB885 Q36897863-6FD3813D-85B0-4F1F-AEDA-51C0EEED94E7 Q37083896-14FC171B-181E-4543-9B51-ED60A83C25CC Q37130458-06626F6D-5019-400E-AC66-E0B66D16DCDC Q37256366-E0FD94FD-337C-4055-BD4B-BDAA8D1484B9 Q37307096-1146EBA5-2537-46E1-90AF-A11395D0CA1C Q41689888-BB15A1FF-4B4B-4B3E-9D4A-2C77529342ED Q42912613-E4084620-2F8B-4BC8-9FF4-D8A7536912CF Q44990505-6992DF11-B020-466F-B78C-773F19884175 Q46933139-AB25941B-9C1F-4B10-B246-CB30605A6CE1

P2860

Highly active antiretroviral therapy and viral response in HIV type 2 infection.

http://www.wikidata.org/entity/Q34548972

description

2004 nî lūn-bûn

@nan

2004 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2004 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2004年の論文

@ja

2004年論文

@yue

2004年論文

@zh-hant

2004年論文

@zh-hk

2004年論文

@zh-mo

2004年論文

@zh-tw

2004年论文

@wuu

name

Highly active antiretroviral therapy and viral response in HIV type 2 infection.

@ast

Highly active antiretroviral therapy and viral response in HIV type 2 infection.

@en

Highly active antiretroviral therapy and viral response in HIV type 2 infection.

@nl

type

label

Highly active antiretroviral therapy and viral response in HIV type 2 infection.

@ast

Highly active antiretroviral therapy and viral response in HIV type 2 infection.

@en

Highly active antiretroviral therapy and viral response in HIV type 2 infection.

@nl

prefLabel

Highly active antiretroviral therapy and viral response in HIV type 2 infection.

@ast

Highly active antiretroviral therapy and viral response in HIV type 2 infection.

@en

Highly active antiretroviral therapy and viral response in HIV type 2 infection.

@nl

P1433

Q34548972-A1F2BAD8-B74B-4D28-B8CD-CE38C356EB60

P1476

Q34548972-5EDB24ED-E50E-4FF9-AE35-39D356EE754E

P2093

Q34548972-0BF804EF-20BD-43C7-9916-5628313D7ABE

Q34548972-1A769D4E-0169-48D9-B503-EBD7B0BDDEDD

Q34548972-32CCEF6A-0BE0-4599-83B8-F76943B25969

Q34548972-381E5CCE-4B8E-4AE2-8FE2-31C165E6C98F

Q34548972-3D663E70-6D83-49E2-BDD8-34216FFC37E9

Q34548972-458AA826-9F65-423C-A9D7-100662EC9FEB

Q34548972-6682040C-2DBE-4D10-B033-1CB6B4055CD4

Q34548972-7039412D-90A7-437B-B99F-257815399CED

Q34548972-7CE2844A-3955-4D1F-87BC-DF0296DF2207

Q34548972-82975818-AC30-4903-ABD3-57649287A401

P2860

Q34548972-13DE428B-F2C4-41F6-B24D-23ED90439DB7

Q34548972-17D27C02-3C37-4298-9155-FACF088474BC

Q34548972-22B95218-B959-42CA-A782-0B31F7E111A4

Q34548972-39763F4B-6885-479A-90A8-8BDCD8B51E21

Q34548972-3C8415C4-2ED3-449D-895C-5839D5C4BDE5

Q34548972-477057A4-4121-40AF-803E-C3C0A83E8D3C

Q34548972-4C2ECF06-73A3-4074-A053-6CB177A978CF

Q34548972-6C217415-33F6-4770-B581-C941BE67CFEB

Q34548972-6EFBB953-853B-49FF-8C3A-939BEE115CFE

Q34548972-728C819D-FDAF-4F7B-8A16-299FE43135B6

P304

Q34548972-C530EF92-473B-43F6-B9CF-9F595B5B4178

P31

Q34548972-CE8FC632-D008-4FC9-B762-1D40409F516E

P356

Q34548972-FD42E5BD-4C9E-4FA2-A97E-F732B0645F95

P407

Q34548972-4DBF01D0-5620-44D5-B467-E7FD8E756EA8

P433

Q34548972-E4D63EA1-A4E4-4442-9D41-8C12F49D96B4

P478

Q34548972-FB2FCFDC-F1A0-4412-8EA5-2B6E3395D1E6

P577

Q34548972-CF6904D2-0905-4A6E-B94B-F80FE5F61E64

P5875

Q34548972-554CA117-D873-40D6-81C0-5C0684F14769

P698

Q34548972-EE634BB5-2836-4128-A838-12BD7F371E9D

P921

Q34548972-DAE037E3-0360-42E4-BD74-259026992AA3

P356

P1433

Clinical Infectious Diseases

P1476

Highly active antiretroviral therapy and viral response in HIV type 2 infection.

@en

P2093

Abdoulaye Dieng Sarr

http://www.w3.org/2001/XMLSchema#string

Christopher Mullins

http://www.w3.org/2001/XMLSchema#string

Geoffrey Eisen

http://www.w3.org/2001/XMLSchema#string

Gerard Coste

http://www.w3.org/2001/XMLSchema#string

Hernan R Chang

http://www.w3.org/2001/XMLSchema#string

Jean-Louis Sankale

http://www.w3.org/2001/XMLSchema#string

Judith J Berger

http://www.w3.org/2001/XMLSchema#string

Margaret Sullivan

http://www.w3.org/2001/XMLSchema#string

Paul R Skolnik

http://www.w3.org/2001/XMLSchema#string

Peter Rice

http://www.w3.org/2001/XMLSchema#string

P2860

3'-Azido-3'-deoxythymidine (BW A509U): an antiviral agent that inhibits the infectivity and cytopathic effect of human T-lymphotropic virus type III/lymphadenopathy-associated virus in vitro

Reduced rate of disease development after HIV-2 infection as compared to HIV-1

An antiviral target on reverse transcriptase of human immunodeficiency virus type 1 revealed by tetrahydroimidazo-[4,5,1-jk] [1,4]benzodiazepin-2 (1H)-one and -thione derivatives

Inhibition of the in vitro infectivity and cytopathic effect of human T-lymphotrophic virus type III/lymphadenopathy-associated virus (HTLV-III/LAV) by 2',3'-dideoxynucleosides

Synthesis and biological activity of novel 1H,3H-thiazolo[3,4-a]benzimidazoles: non-nucleoside human immunodeficiency virus type 1 reverse transcriptase inhibitors

Slower heterosexual spread of HIV-2 than HIV-1.

Isolation of a new human retrovirus from West African patients with AIDS.

Strategies for antiviral therapy in AIDS.

Analysis of HIV-2 RT mutants provides evidence that resistance of HIV-1 RT and HIV-2 RT to nucleoside analogs involves a repositioning of the template-primer.

Potency comparison of peptidomimetic inhibitors against HIV-1 and HIV-2 proteinases: design of equipotent lead compounds.

P304

1771-1779

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1086/421390

http://www.w3.org/2001/XMLSchema#string

P407

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

38

http://www.w3.org/2001/XMLSchema#string

P577

2004-05-25T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

8480095

http://www.w3.org/2001/XMLSchema#string

P698

15227626

http://www.w3.org/2001/XMLSchema#string

P921

antiretroviral drug